OreofeOOdejideMDMPH

Hematologic Oncology

Assistant Professor of Medicine, Harvard Medical School Physician, Dana-Farber Cancer Institute

Dr. Odejide is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
450 Brookline Avenue
Boston, MA 02215
Phone+1 617-632-3470

Fax+1 617-632-5175

Dr. Oreofe Odejide is an oncologist in Boston, MA and is affiliated with multiple hospitals in the area, including Dana-Farber Cancer Institute and Brigham and Women's Hospital. She received her medical degree from Howard University College of Medicine and has been in practice 9 years. She specializes in hematologic oncology.

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2011 - 2014
Brigham and Women's HospitalResidency, Internal Medicine, 2008 - 2011
Howard University College of MedicineClass of 2008
Harvard T.H Chan School of Public HealthMPH, Clinical Effectiveness

UPLYFT For Lymphoma Survivors Start of enrollment: 2022 Feb 08
Recruiting
Not Applicable
Roles: Principal Investigator, Contact
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia Start of enrollment: 2022 Jun 01
Recruiting
Not Applicable
Roles: Contact
Home Transfusion for HEME Start of enrollment: 2024 Aug 01
Recruiting
Not Applicable
Roles: Contact, Principal Investigator

PubMed

Preferred and Actual Location of Death in Adolescents and Young Adults With Cancer.
Oreofe O Odejide, Colin Cernik, Hajime Uno, Lauren Fisher, Lanfang Xu
JAMA Network Open. 2025-01-02
2 citations
Early palliative care perceptions by patients with cancer and primary caregivers: metaphorical language.
Elena Bandieri, Sarah Bigi, Melissa Nava, Eleonora Borelli, Carlo Adolfo Porro
BMJ Supportive & Palliative Care. 2024-12-19
Integrative epidemiology and immunotranscriptomics uncover a risk and potential mechanism for cutaneous lymphoma unmasking or progression with dupilumab therapy.
Javier S Cabrera-Perez, Vincent J Carey, Oreofe O Odejide, Sonal Singh, Thomas S Kupper
The Journal of Allergy and Clinical Immunology. 2024-11-07

Abstracts/Posters

Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United St...
Oreofe O. Odejide, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Moving Forward When It Is Time to Stop
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Preferred vs. Actual Location of Death: A Mismatch for Young Cancer PatientsJanuary 14th, 2025
Share on Twitter Share on Facebook Share on LinkedIn Olanzapine Reduces Nausea and Improves Quality of Life for Patients with Cancer During ChemotherapySeptember 24th, 2024
Study Finds Fewer Blood Cancer Patients Get Hospice CareMay 22nd, 2017
Join now to see all